FDA's $2.1 Billion Acquisition of Rare Sleep Disorder Treatment: What’s the Target?

U.S. sleep-disorder drug developer Avadel Pharmaceuticals plc (Nasdaq: AVDL) was officially acquired by Alkermis on the 12th (local time), transferring regulatory ownership of LUMRYZ—the once-daily narcolepsy treatment approved by the U.S. FDA—to its new parent. LUMRYZ secured seven years of orphan-drug exclusivity after FDA approvals for adults in May 2023 and for pediatric and adolescent patients in October 2024, and is available only under a REMS program due to its abuse potential. Under the acquisition agreement that took effect immediately, Alkermis will assume the existing FDA approval, exclusivity and REMS framework, integrating LUMRYZ and Avadel’s sleep-disorder pipeline in development. The deal also carries a contingent value right (CVR) that will pay current shareholders up to $1.50 per share if LUMRYZ gains FDA approval for idiopathic hypersomnia (IH).

Headquartered in Ireland, Avadel is a Nasdaq-listed biotech focused on rare sleep disorders. The company has highlighted LUMRYZ’s convenience—replacing the traditional two-dose nightly oxybate regimen with a single pre-bedtime dose. Based on Phase III data demonstrating clinical superiority over immediate-release oxybate, the FDA granted seven years of orphan-drug exclusivity for adult and for patients aged seven and older. Beyond narcolepsy, Avadel expanded its development to central hypersomnolence disorders, including IH, securing an additional orphan-drug designation (ODD) for IH in June 2025 to support further indications. Upon closing, Avadel’s common shares will be delisted from Nasdaq and its registration under the U.S. Securities Exchange Act will be withdrawn, ending its tenure as an independent public company.

Recent events around Avadel amounted to preparatory steps for this takeover. In November 2025, the company received an unsolicited offer from rival Lundbeck valuing Avadel at up to $23 per share. However, Avadel’s board backed the original deal with Alkermis—$18.50 in cash plus a CVR of up to $1.50 linked to final FDA approval for IH—and shareholders approved the Alkermis proposal at the January 2026 annual meeting. Earlier, in fall 2025, Avadel resolved all litigation over LUMRYZ through a global agreement with Jazz Pharmaceuticals, establishing a long-term license and royalty structure. In Q3 of the same year, it further expanded its sleep-disorder portfolio by licensing global rights to its next-generation “non-salt” oxybate candidate, valiloxybate. This series of risk-mitigation measures and pipeline expansions provides the core foundation for LUMRYZ and related assets to underpin Alkermis’s entry into the sleep-medicine market.